ES2308223T3 - Formulaciones antitum0rales que comprenden defibrotido solo o en combinacion con otros agentes antitumorales. - Google Patents

Formulaciones antitum0rales que comprenden defibrotido solo o en combinacion con otros agentes antitumorales. Download PDF

Info

Publication number
ES2308223T3
ES2308223T3 ES04764686T ES04764686T ES2308223T3 ES 2308223 T3 ES2308223 T3 ES 2308223T3 ES 04764686 T ES04764686 T ES 04764686T ES 04764686 T ES04764686 T ES 04764686T ES 2308223 T3 ES2308223 T3 ES 2308223T3
Authority
ES
Spain
Prior art keywords
combination
tumor
cells
formulations
defibroted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04764686T
Other languages
English (en)
Spanish (es)
Inventor
Laura Iris Ferro
Massimo Iacobelli
Paul Richardson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gentium SRL
Original Assignee
Gentium SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium SRL filed Critical Gentium SRL
Application granted granted Critical
Publication of ES2308223T3 publication Critical patent/ES2308223T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES04764686T 2003-09-05 2004-08-27 Formulaciones antitum0rales que comprenden defibrotido solo o en combinacion con otros agentes antitumorales. Expired - Lifetime ES2308223T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
ITMI03A1714 2003-09-05
US53934404P 2004-01-28 2004-01-28
US539344P 2004-01-28

Publications (1)

Publication Number Publication Date
ES2308223T3 true ES2308223T3 (es) 2008-12-01

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04764686T Expired - Lifetime ES2308223T3 (es) 2003-09-05 2004-08-27 Formulaciones antitum0rales que comprenden defibrotido solo o en combinacion con otros agentes antitumorales.

Country Status (23)

Country Link
US (2) US8551967B2 (https=)
EP (1) EP1660100B1 (https=)
JP (1) JP4671962B2 (https=)
KR (1) KR20060061367A (https=)
CN (1) CN100490820C (https=)
AT (1) ATE399558T1 (https=)
AU (1) AU2004269896B2 (https=)
BR (1) BRPI0414114A (https=)
CA (1) CA2537226C (https=)
DE (1) DE602004014787D1 (https=)
DK (1) DK1660100T3 (https=)
ES (1) ES2308223T3 (https=)
IL (1) IL173785A0 (https=)
IS (1) IS8334A (https=)
IT (1) ITMI20031714A1 (https=)
MX (1) MXPA06002489A (https=)
NO (1) NO20061402L (https=)
PT (1) PT1660100E (https=)
RS (1) RS20060154A (https=)
RU (1) RU2348413C2 (https=)
UA (1) UA83500C2 (https=)
WO (1) WO2005023273A1 (https=)
ZA (1) ZA200601852B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094916A1 (en) * 2005-03-03 2006-09-14 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
JP2020530004A (ja) * 2017-08-03 2020-10-15 ジャズ ファーマシューティカルズ アイルランド リミテッド 核酸を高濃度で含む製剤
CN112236149A (zh) 2018-04-12 2021-01-15 贾兹制药公司 用于预防和治疗细胞因子释放综合征和与免疫耗竭相关的神经毒性的去纤苷
WO2020118165A1 (en) 2018-12-07 2020-06-11 Jazz Pharmaceuticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
HK1044896A1 (zh) * 1997-04-28 2002-11-08 Burcoglu Arsinur 治疗hiv感染和与之有关的继发感染的方法
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
CA2433225A1 (en) * 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
UA83628C2 (ru) * 2002-05-31 2008-08-11 Клиникум Дер Универзитет Регенсбург Способ защиты эндотелиальных и эпителиальных клеток во время трансплантации алогенных стволовых клеток
RU2005101621A (ru) * 2002-07-01 2005-11-20 Савиент Фармасьютикалс, Инк. (Us) Антитела и их применения
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2006094916A1 (en) 2005-03-03 2006-09-14 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Also Published As

Publication number Publication date
ITMI20031714A1 (it) 2005-03-06
WO2005023273A1 (en) 2005-03-17
UA83500C2 (uk) 2008-07-25
CN1845746A (zh) 2006-10-11
IS8334A (is) 2006-02-28
RU2348413C2 (ru) 2009-03-10
CN100490820C (zh) 2009-05-27
JP2007504194A (ja) 2007-03-01
DE602004014787D1 (de) 2008-08-14
US20140005256A1 (en) 2014-01-02
MXPA06002489A (es) 2006-06-20
RU2006109210A (ru) 2007-10-10
US20060211646A1 (en) 2006-09-21
NO20061402L (no) 2006-03-28
CA2537226C (en) 2016-05-03
JP4671962B2 (ja) 2011-04-20
CA2537226A1 (en) 2005-03-17
US8551967B2 (en) 2013-10-08
KR20060061367A (ko) 2006-06-07
EP1660100A1 (en) 2006-05-31
AU2004269896A1 (en) 2005-03-17
ZA200601852B (en) 2007-06-27
IL173785A0 (en) 2006-07-05
BRPI0414114A (pt) 2006-10-31
PT1660100E (pt) 2008-10-14
DK1660100T3 (da) 2008-11-10
RS20060154A (sr) 2008-08-07
AU2004269896B2 (en) 2009-11-19
EP1660100B1 (en) 2008-07-02
ATE399558T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
US20140005256A1 (en) Formulations with anti-tumour action
Jin et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery
Gorelik et al. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice
ES2848025T3 (es) Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
US20030166617A1 (en) Combination therapies with vascular damaging activity
Tretiakova et al. Liposomal formulation of a melphalan lipophilic prodrug: Studies of acute toxicity, tolerability, and antitumor efficacy
Aristei et al. Total Marrow/Lymphoid irradiation in the conditioning regimen for haploidentical T-Cell-Depleted hematopoietic stem cell transplantation for acute myeloid leukemia: The perugia experience
Ezcurra-Hualde et al. Liposomal encapsulation of cholecalciferol mitigates in vivo toxicity and delays tumor growth
Sava et al. Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung carcinoma
Karita et al. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine
Dhalluin et al. Chemotherapy and radiotherapy for mesothelioma
ES2917208T3 (es) Tratamiento de pacientes con trasplante de células madre hematopoyéticas
Ruggeri et al. Cynthia Aristei, Simonetta Saldi, Antonio Pierini
ES2900839T3 (es) Combinaciones quimioterapéuticas de péptidos antimicrobianos catiónicos y quimioterapéuticos
Rastinfard Aqueous decomposition behaviour of oxygen releasing peroxy-compounds and assessment of their therapeutic potential
US20190239937A1 (en) Augmentation of Abscopal Effect of Cryotherapy and other Tumor Cell Death by Anti-angiogenic and Anti-tumor Vaccination
Chen et al. Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity
Adams et al. The Preclinical Development of FTY720, A Sphingosine-1-Phosphate Receptor Modulator, as a Novel Targeting Therapy Against Breast Cancer
Wang et al. Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy. Pharmaceutics 2021, 13, 166
WO2025155926A1 (en) Nad(h) nanoparticles and methods of reducing vein graft injury and improving vein graft health
Garg et al. Damage-associated molecular patterns: revealing the molecular communication between dying cancer cells and the immune system
Elias Preoperative Immune Manipulation of the Primary Site in Melanoma can Initiate Anti-Tumor Autoimmunity: A New Approach to Adjuvant Therapy
Giuliani et al. Combination chemotherapy and surgical adjuvant chemotherapy on MS-2 sarcoma and lung metastases in mice
Gilmore Nanometer-Scale, Particle-Based Immunotherapy for Cancer Treatment (LDRD Final Report: 17-LW-051)
Berger Animal Models of Cancer Caused by Immunosuppression